NEW YORK (GenomeWeb) – Epigenomics today reported a nearly 5 percent decline in first quarter revenues, primarily due to the conclusion of agreements with licensing partners for the sale of its products.
NEW YORK (GenomeWeb) – Epigenomics today reported a nearly 5 percent decline in first quarter revenues, primarily due to the conclusion of agreements with licensing partners for the sale of its products.
...and receive Daily News bulletins.
Already have a 360Dx or GenomeWeb account?
Login Now.
Don't have a 360Dx or GenomeWeb account?
Register for Free.